Clostridiaceae

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

Retrieved on: 
Tuesday, August 22, 2023
Neuraxis, International Classification of Functioning, Disability and Health, Disability, Clinical trial, Blautia, Irritable bowel syndrome, Inflammation, Abdominal pain, Publication, Patient, Clostridiaceae, IBS, Hospital, NYSE

Bacterial species in the Clostridiaceae family were more abundant in IBS patients compared to healthy control group.

Key Points: 
  • Bacterial species in the Clostridiaceae family were more abundant in IBS patients compared to healthy control group.
  • After treatment with IB-Stim, there were notable decreases in the clostridial species which have previously been implicated in gastrointestinal pro-inflammatory states.
  • Also, noted after treatment was a decrease in bacterial pathways of long-chain fatty acid synthesis, suggesting modulation of the microbiome and perhaps related inflammation.
  • According to the authors, “this suggests that patients with a specific microbial signature have a more favorable response to therapy.”2

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Antibiotic, Fidaxomicin

It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Retrieved on: 
Monday, July 12, 2021
Medical specialties, Bacteria, Microbiology, Glycopeptide antibiotics, Environmental microbiology, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Ridinilazole, Gut microbiota, Vancomycin

Ridinilazole is Summit Therapeutics investigational first-in-class drug currently in two pivotal Phase III Ri-CoDIFy clinical trials.

Key Points: 
  • Ridinilazole is Summit Therapeutics investigational first-in-class drug currently in two pivotal Phase III Ri-CoDIFy clinical trials.
  • In a Phase II study, treatment with ridinilazole compared to vancomycin demonstrated a significant sparing effect on the gut microbiome, supporting the production of protective secondary bile acids.
  • This is believed to be the primary mechanism through which ridinilazole elicits its bactericidal action against C. difficile bacteria.
  • The combination of these studies and discoveries provide us with further data in support of the intended efficacy of ridinilazole.

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Pharmaceutical, Health, Health, Life sciences, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Orphan drug

b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.

Key Points: 
  • b'Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.\nA live audio webcast of the panel will be available under the \xe2\x80\x9cInvestors and News\xe2\x80\x9d section of Seres\xe2\x80\x99 website.
  • Seres\xe2\x80\x99 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
  • The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.
  • For more information, please visit www.serestherapeutics.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/\n'

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Clinical medicine, Gastroenterology, Diarrhea, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Feces, C. Diff

\xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.

Key Points: 
  • \xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.
  • infection.\nClostridioides difficile, or C. difficile, infection (CDI) is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration.
  • Accordingly, readers should not place undue reliance on forward-looking statements or information.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.\n'

Peggy Lillis Foundation releases Care Guide for Patients with C. diff Infections

Retrieved on: 
Friday, March 26, 2021
Diarrhea, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, C. Diff, Microbiology, Infection, Clinical medicine

BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."

Key Points: 
  • BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."
  • The Care Guide provides patients with C. difficile infections and their caregivers wide-ranging information about the disease, its treatment and its long-term impacts in accessible language.
  • The Guide includes easy to understand information on topics C. diff patients frequently ask about, including how C. diff is spread, getting an accurate diagnosis, treatment options for primary and recurrent C. diff, preventing C. diff spread in the home, and socio-emotional impacts of recurrent C. diff.
  • About Peggy Lillis Foundation for C. diff Education & Advocacy
    Founded in response to the April 2010 death of 56-year-old kindergarten teacher, Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) is the leading national organization dedicated to combating C. difficile infections through educating the public, empowering advocates and shaping policy.

Peggy Lillis Foundation and Ferring Pharmaceuticals Partner to Support Patients with C. difficile Infection

Retrieved on: 
Thursday, March 11, 2021
Bacteria, Medical specialties, Microbiology, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Firmicutes, Ferring Pharmaceuticals, CDI, Gut flora

Joining forces, PLF and Ferring are eager to continue helping people living with CDI and their loved ones.

Key Points: 
  • Joining forces, PLF and Ferring are eager to continue helping people living with CDI and their loved ones.
  • "We founded PLF ten years ago to fight the infection that took our mother Peggy from us.
  • "We are thrilled to continue our partnership with the Peggy Lillis Foundation, an advocacy group that has done so much for the CDI community," said Dr. Edward Trott, Chief Patient Officer, Ferring Pharmaceuticals.
  • Ferring is committed to exploring the crucial link between the gut microbiome and human health, beginning with the threat of recurrent Clostridioides difficile infections.

Worldwide Point of Care Diagnostics Industry to 2028 - Rising Preference Towards Home Healthcare Presents Opportunities

Retrieved on: 
Thursday, March 4, 2021
Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Health care, Infection, Articles, Medical specialties

Global Point of Care (PoC) Diagnostics Market, by Infectious Diseases, by Region, 2016-2028 (USD Million)

Key Points: 
  • Global Point of Care (PoC) Diagnostics Market, by Infectious Diseases, by Region, 2016-2028 (USD Million)
    5.7.2.1.
  • Global Point of Care (PoC) Diagnostics Market, by Clostridium Difficile, by Region, 2016-2028 (USD Million)
    5.7.4.1.
  • Global Point of Care (PoC) Diagnostics Market, by Primary Care Systems, by Region, 2016-2028 (USD Million)
    5.7.9.1.
  • Global Point of Care (PoC) Diagnostics Market, by Assisted Living Healthcare Facilities, by Region, 2016-2028 (USD Million)
    8.7.1.

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

Retrieved on: 
Thursday, November 12, 2020
Medical specialties, Clostridiaceae, Gram-positive bacteria, Microbiology, Infectious diseases, Antibiotic-resistant bacteria, Clostridioides difficile, CDI, Clostridioides, COVID-19 pandemic

Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.

Key Points: 
  • Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.
  • 40% of patients suffering a Clostridioides difficile infection (CDI) have severe forms, associated with high morbidity and mortality rates.
  • DEINOVE is a French biotech company, a pioneer in the exploitation of the unknown or little-known part of biodiversity.
  • DEINOVE, located in the Euromdecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally.

Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol

Retrieved on: 
Monday, November 9, 2020
Bacteria, Medical specialties, Microbiology, Clostridiaceae, Gram-positive bacteria, Antibiotic-resistant bacteria, Clostridioides difficile, Clostridium difficile, Clostridium, Steatohepatitis, Microbiome

The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.

Key Points: 
  • The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.
  • MyBiotics' microbiome therapeutic technology enables the design of bespoke microbial consortia profiles based on MyBiotics' unique culturing and fermentation capabilities.
  • MyBiotics' lead product candidate for treatment of recurring clostridium difficile infection (CDI), MBX-SD-202, is expected to enter Phase I clinical trials in 2021.
  • "The collaboration, which aims to elevate the response rate of Aramchol, is part of our overall plan to maximize Aramchol clinical efficacy.